Phase II Interim Analysis of FcRn Inhibitor Rozanolixizumab in Adult Patients With Primary Immune Thrombocytopenia

December 9-12, 2017; Atlanta, Georgia
Most treatment-emergent adverse events were mild to moderate in adult ITP patients receiving 4 or 7 mg/kg of rozanolixizumab subcutaneously.
Format: Microsoft PowerPoint (.ppt)
File Size: 227 KB
Released: December 20, 2017

Acknowledgements

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation

Related Content

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)

David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: June 22, 2022

Downloadable slideset from a local live webinar developed by lymphoma experts with guidance on the management of indolent lymphomas

Elizabeth Brém, MD Christopher R. Flowers, MD, MS Released: June 21, 2022

Downloadable slideset on clinical considerations in managing inoperable plexiform neurofibromas in patients with NF1, from Clinical Care Options (CCO)

Carlos Romo, MD Released: June 20, 2022

Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 20, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings